CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity

ABSTRACT

Background

Rising cancer-related mortality underscores the importance of biomarkers for treatment and prognosis, with Chromosome Segregation 1 Like (CSE1L) linked to various cancers yet its roles remain partially understood. This study investigates CSE1L’s expression and oncogenic mechanisms in solid tumors.

Research design and methods

We analyzed multi-omics data from 31 solid tumors, measured CSE1L in 41 head and neck carcinoma patients post-chemotherapy via qRT-PCR, and evaluated the impact of CSE1L knockdown on cell proliferation in A549 and HepG2 cells.

Results

In this study, we observed significantly elevated levels of CSE1L RNA in 13 tumor tissues and protein levels in 8 tumor tissues compared to their corresponding adjacent normal tissues. Additionally, our investigation unveiled a correlation between heightened CSE1L expression in tumor tissues and worsened patient prognosis, poor response to immunotherapy, and diminished effectiveness of neoadjuvant chemotherapy. Through an analysis of CSE1L mechanisms, we discovered its potential involvement in promoting tumor cell proliferation, enhancing drug resistance, and influencing immune infiltration, thereby impacting patient prognosis and treatment outcomes. Finally, we delved into the potential mechanisms underlying upregulation of CSE1L in tumor tissues.

Conclusion

Our findings demonstrate that CSE1L promotes tumor development in various malignancies, highlighting its potential as both a therapeutic target and prognostic indicator.

KEYWORDS:

• CSEL1
• multi-omics
• bioinformatics
• qRT-PCR
• CRISPR screening

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Authors’ contributions

This study conception and design by JG Fang and R Wang. Material preparation, data collection and analysis were performed by HY Li, ZH Ruan, XY Li and LW Wang. The loss-of-function assays of CSE1L was performed by LW Wang, HY Li and YF Yang. The first draft of the manuscript was written by HY Li, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethics statement

The study protocol was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. All patients provided informed consent to allow their tissues to be used in the study before surgery.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/1744666X.2024.2356747

Acknowledgments

Thanks to every member of the team for their valuable comments and help.

Additional information

Funding

This study was supported by Capital Health Research and Development of Special Fund [2022-1-2051], National Natural Science Foundation of China [82002880], Beijing Medical Award Foundation [XYJL-2022-0072-0005], Beijing Municipal Administration of Hospitals Incubating Program [PX2021008].